AtriCure Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AtriCure stock.
View analyst ratings for AtriCure or view top-rated stocks.

5 analysts have issued 12-month target prices for AtriCure's shares. Their ATRC stock forecasts range from $55.00 to $110.00. On average, they expect AtriCure's share price to reach $83.20 in the next twelve months. This suggests a possible upside of 104.9% from the stock's current price.
View analysts' price targets for AtriCure or view top-rated stocks among Wall Street analysts.

AtriCure's stock was trading at $69.53 at the beginning of the year. Since then, ATRC stock has decreased by 41.6% and is now trading at $40.60.
View the best growth stocks for 2022 here.

AtriCure is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for AtriCure.

AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings data on Tuesday, May, 3rd. The medical device company reported ($0.33) earnings per share for the quarter, hitting the consensus estimate of ($0.33). The medical device company earned $74.58 million during the quarter, compared to analysts' expectations of $71.17 million. AtriCure had a net margin of 17.93% and a negative trailing twelve-month return on equity of 11.66%. The company's revenue for the quarter was up 25.8% on a year-over-year basis. During the same period last year, the company earned ($0.32) EPS.
View AtriCure's earnings history.

AtriCure issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of -$1.12--$1.07 for the period, compared to the consensus EPS estimate of -$1.05. The company issued revenue guidance of $318.00 million-$330.00 million, compared to the consensus revenue estimate of $321.65 million.

25 employees have rated AtriCure CEO Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among AtriCure's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of ATRC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

AtriCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.20%), BlackRock Inc. (7.88%), Invesco Ltd. (6.19%), First Light Asset Management LLC (2.95%), Champlain Investment Partners LLC (2.76%) and State Street Corp (2.20%). Company insiders that own AtriCure stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends for AtriCure.

ATRC stock was sold by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Bank of New York Mellon Corp, Emerald Mutual Fund Advisers Trust, BlackRock Inc., Oak Ridge Investments LLC, Tamarack Advisers LP, Rothschild & Co. Asset Management US Inc., and BNP PARIBAS ASSET MANAGEMENT Holding S.A.. Company insiders that have sold AtriCure company stock in the last two years include Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin, and Vinayak Doraiswamy.
View insider buying and selling activity for AtriCure or view top insider-selling stocks.

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., First Light Asset Management LLC, Bellevue Group AG, Wasatch Advisors Inc., WCM Investment Management LLC, Loomis Sayles & Co. L P, Champlain Investment Partners LLC, and Congress Asset Management Co. MA. Company insiders that have bought AtriCure stock in the last two years include Regina E Groves, and Scott William Drake.
View insider buying and selling activity for AtriCure or or view top insider-buying stocks.

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRC stock can currently be purchased for approximately $40.60.

AtriCure (NASDAQ:ATRC) has a market capitalization of $1.88 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or $1.119990 on an earnings per share basis.

AtriCure employs 875 workers across the globe.

AtriCure was founded in 2000.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for AtriCure is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at [email protected], or via fax at 513-755-4567.